The Pharmacist’s Role in Navigating Toxicity With TKIs

EP: 1.NCCN Guidelines and Early Response Monitoring in Chronic Myeloid Leukemia

EP: 2.Shifting Therapeutic Urgency and TKI Strategy

EP: 3.Leveraging Trial Data to Guide Frontline TKI Use

EP: 4.Milestones That Matter: Using Molecular and Clinical Benchmarks to Guide CML Therapy

EP: 5.Reconsidering Later-Line Therapies in CML Management

Now Viewing

EP: 6.The Pharmacist’s Role in Navigating Toxicity With TKIs

Video content above is prompted by the following:

Pharmacists play instrumental roles in managing chronic myeloid leukemia (CML) treatment-related adverse effects, including myelosuppression, fluid retention, and corrected QT (QTc) prolongation, through comprehensive monitoring protocols and patient education. Regular laboratory monitoring with weekly or biweekly complete blood counts helps identify myelosuppression early, allowing for appropriate dose adjustments to maintain both safety and efficacy. Proactive monitoring strategies enable health care teams to anticipate and manage toxicities before they become treatment limiting, ensuring optimal patient outcomes and treatment continuation.

Effective CML management requires thorough patient education about potential adverse effects and warning signs, with pharmacists providing crucial counseling on recognizing symptoms such as sudden weight gain from fluid retention or cardiac symptoms suggesting QTc prolongation. Patient education includes practical guidance on monitoring for periorbital edema with imatinib, recognizing signs of fluid retention, and understanding when to contact health care providers. This comprehensive education approach empowers patients to actively participate in their care while ensuring early detection and management of treatment-related complications.

Pharmacists contribute significantly to CML treatment safety by reviewing medication profiles for potential interactions that could enhance toxicity risks, particularly QTc prolongation when combined with other medications. Comprehensive medication reviews help identify and minimize interaction risks while providing recommendations for safer therapeutic alternatives when possible. This pharmacist-led safety optimization ensures that patients with CML receive the most effective treatment regimens while minimizing preventable adverse events and drug interactions that could compromise treatment success.